Sapphary

Sapphary is a San Diego-based biotechnology company specializing in the discovery and development of novel small molecule therapeutics through its proprietary molecular glue degrader (MGD) platform. The company focuses on targeting undruggable proteins by harnessing the body's natural ubiquitin-proteasome system to induce the selective degradation of disease-causing proteins. Sapphary's primary therapeutic focus is on oncology and immunology, aiming to develop highly potent and selective oral drugs for patients with limited treatment options. Led by a team of industry veterans from organizations such as Amgen and Takeda, the company is currently in the pre-clinical stage of development. Sapphary leverages advanced structural biology and computational modeling to identify unique protein-protein interactions that can be stabilized by molecular glues.